324 related articles for article (PubMed ID: 9918722)
1. Refined crystal structures of native human angiogenin and two active site variants: implications for the unique functional properties of an enzyme involved in neovascularisation during tumour growth.
Leonidas DD; Shapiro R; Allen SC; Subbarao GV; Veluraja K; Acharya KR
J Mol Biol; 1999 Jan; 285(3):1209-33. PubMed ID: 9918722
[TBL] [Abstract][Full Text] [Related]
2. Crystallographic studies on structural features that determine the enzymatic specificity and potency of human angiogenin: Thr44, Thr80, and residues 38-41.
Holloway DE; Chavali GB; Hares MC; Baker MD; Subbarao GV; Shapiro R; Acharya KR
Biochemistry; 2004 Feb; 43(5):1230-41. PubMed ID: 14756559
[TBL] [Abstract][Full Text] [Related]
3. Structural features that determine the enzymatic potency and specificity of human angiogenin: threonine-80 and residues 58-70 and 116-123.
Shapiro R
Biochemistry; 1998 May; 37(19):6847-56. PubMed ID: 9578571
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of murine angiogenin-2 and -3-probing 'structure--function' relationships amongst angiogenin homologues.
Iyer S; Holloway DE; Acharya KR
FEBS J; 2013 Jan; 280(1):302-18. PubMed ID: 23170778
[TBL] [Abstract][Full Text] [Related]
5. Crystallographic studies on the role of the C-terminal segment of human angiogenin in defining enzymatic potency.
Leonidas DD; Shapiro R; Subbarao GV; Russo A; Acharya KR
Biochemistry; 2002 Feb; 41(8):2552-62. PubMed ID: 11851402
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of human angiogenin reveals the structural basis for its functional divergence from ribonuclease.
Acharya KR; Shapiro R; Allen SC; Riordan JF; Vallee BL
Proc Natl Acad Sci U S A; 1994 Apr; 91(8):2915-9. PubMed ID: 8159679
[TBL] [Abstract][Full Text] [Related]
7. Three-dimensional structure of a human pancreatic ribonuclease variant, a step forward in the design of cytotoxic ribonucleases.
Pous J; Canals A; Terzyan SS; Guasch A; Benito A; Ribó M; Vilanova M; Coll M
J Mol Biol; 2000 Oct; 303(1):49-60. PubMed ID: 11021969
[TBL] [Abstract][Full Text] [Related]
8. Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity.
Boix E; Wu Y; Vasandani VM; Saxena SK; Ardelt W; Ladner J; Youle RJ
J Mol Biol; 1996 Apr; 257(5):992-1007. PubMed ID: 8632481
[TBL] [Abstract][Full Text] [Related]
9. Mutational analysis of the complex of human RNase inhibitor and human eosinophil-derived neurotoxin (RNase 2).
Teufel DP; Kao RY; Acharya KR; Shapiro R
Biochemistry; 2003 Feb; 42(6):1451-9. PubMed ID: 12578357
[TBL] [Abstract][Full Text] [Related]
10. X-ray crystallographic structure of recombinant eosinophil-derived neurotoxin at 1.83 A resolution.
Mosimann SC; Newton DL; Youle RJ; James MN
J Mol Biol; 1996 Jul; 260(4):540-52. PubMed ID: 8759319
[TBL] [Abstract][Full Text] [Related]
11. Molecular recognition of human angiogenin by placental ribonuclease inhibitor--an X-ray crystallographic study at 2.0 A resolution.
Papageorgiou AC; Shapiro R; Acharya KR
EMBO J; 1997 Sep; 16(17):5162-77. PubMed ID: 9311977
[TBL] [Abstract][Full Text] [Related]
12. Toward rational design of ribonuclease inhibitors: high-resolution crystal structure of a ribonuclease A complex with a potent 3',5'-pyrophosphate-linked dinucleotide inhibitor.
Leonidas DD; Shapiro R; Irons LI; Russo N; Acharya KR
Biochemistry; 1999 Aug; 38(32):10287-97. PubMed ID: 10441122
[TBL] [Abstract][Full Text] [Related]
13. Crystal structure of human angiogenin with an engineered loop exhibits conformational flexibility at the functional regions of the molecule.
Thiyagarajan N; Acharya KR
FEBS Open Bio; 2013; 3():65-70. PubMed ID: 23772376
[TBL] [Abstract][Full Text] [Related]
14. Crystal structures of ribonuclease A complexes with 5'-diphosphoadenosine 3'-phosphate and 5'-diphosphoadenosine 2'-phosphate at 1.7 A resolution.
Leonidas DD; Shapiro R; Irons LI; Russo N; Acharya KR
Biochemistry; 1997 May; 36(18):5578-88. PubMed ID: 9154942
[TBL] [Abstract][Full Text] [Related]
15. High-resolution crystal structures of ribonuclease A complexed with adenylic and uridylic nucleotide inhibitors. Implications for structure-based design of ribonucleolytic inhibitors.
Leonidas DD; Chavali GB; Oikonomakos NG; Chrysina ED; Kosmopoulou MN; Vlassi M; Frankling C; Acharya KR
Protein Sci; 2003 Nov; 12(11):2559-74. PubMed ID: 14573867
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of bovine angiogenin at 1.5-A resolution.
Acharya KR; Shapiro R; Riordan JF; Vallee BL
Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2949-53. PubMed ID: 7708754
[TBL] [Abstract][Full Text] [Related]
17. Binding of phosphate and pyrophosphate ions at the active site of human angiogenin as revealed by X-ray crystallography.
Leonidas DD; Chavali GB; Jardine AM; Li S; Shapiro R; Acharya KR
Protein Sci; 2001 Aug; 10(8):1669-76. PubMed ID: 11468363
[TBL] [Abstract][Full Text] [Related]
18. The crystal structure of eosinophil cationic protein in complex with 2',5'-ADP at 2.0 A resolution reveals the details of the ribonucleolytic active site.
Mohan CG; Boix E; Evans HR; Nikolovski Z; Nogués MV; Cuchillo CM; Acharya KR
Biochemistry; 2002 Oct; 41(40):12100-6. PubMed ID: 12356310
[TBL] [Abstract][Full Text] [Related]
19. Mapping the ribonucleolytic active site of eosinophil-derived neurotoxin (EDN). High resolution crystal structures of EDN complexes with adenylic nucleotide inhibitors.
Leonidas DD; Boix E; Prill R; Suzuki M; Turton R; Minson K; Swaminathan GJ; Youle RJ; Acharya KR
J Biol Chem; 2001 May; 276(18):15009-17. PubMed ID: 11154698
[TBL] [Abstract][Full Text] [Related]
20. Mutagenesis of residues flanking Lys-40 enhances the enzymatic activity and reduces the angiogenic potency of angiogenin.
Harper JW; Fox EA; Shapiro R; Vallee BL
Biochemistry; 1990 Aug; 29(31):7297-302. PubMed ID: 1698454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
